转自：北京日报客户端 当保险业告别了股东大水漫灌的黄金时代，资本补充成为中小险企的常态化课题。近期，"茅台系"险企 华贵人寿保险股份有限公司（以下简称"华贵人寿"）完成新一轮增资。根据贵州金融监管局发布的关于 华贵人寿变更注册资本批复，同意华贵人寿增加注册资本6.15亿元，由20亿元变更为26.15亿元。 6.15亿元新增资本的注入似乎缓解了短期资本压力。不过，华贵人寿年初启动的25亿—45亿元大规模募 资项目仍在持续挂牌，且已历经多次延期。这背后折射出中小寿险企业在行业转型期的普遍困境。 6.15亿元增资落地 12月19日，贵州金融监管局发布的批复信息显示，同意华贵人寿增加注册资本6.15亿元，由20亿元变更 为26.15亿元。 按照行业惯例，保险公司增资前，一般会在保险业协会官网先披露变更注册资本相关决议及具体的方 案。但华贵人寿并没有前述环节，仅仅在增资获批后发布了变更注册资本的公告，且在公告中并未公开 具体的出资方及出资比例情况。 根据公告信息，华贵人寿增资相关议案为该公司2024年第1次（临时）股东大会审议通过。但华贵人寿 此前披露的信息显示，该公司2024年第1次（临时）股东大会会议审议通过了《关 ...

Core Viewpoint - Fosun United Health Insurance Co., Ltd. has successfully completed a strategic capital increase of 810 million yuan, raising its registered capital from 694.44 million yuan to 1.01085 billion yuan, marking a significant milestone in its capital strength and shareholder structure [1][2]. Group 1: Capital Increase Details - On September 22, 2023, Fosun United Health received approval from the Guangdong Financial Regulatory Bureau for a capital increase of 810 million yuan [1]. - The capital increase involved new shareholders, including the International Finance Corporation (IFC) and the Asian Development Bank (ADB), while existing shareholder Fosun Pharma increased its stake from 14% to 20.05% [1]. - The capital increase is expected to provide a solid foundation for the company's future high-quality development and business expansion [1]. Group 2: Financial Performance - Since its establishment in January 2017, Fosun United Health has seen a continuous expansion in premium income, with insurance business revenue growing from 5.9 million yuan in 2017 to 5.226 billion yuan in 2024 [2]. - In the first half of 2025, the company achieved insurance business revenue of 3.642 billion yuan, representing a year-on-year growth of 31.09%, and net profit of 33 million yuan, marking a return to profitability [2]. - Despite previous attempts at capital increases in 2018, 2019, 2021, and 2023 failing, the company received cash donations from shareholders to supplement its capital during that period [2]. Group 3: Solvency Position - As of the end of 2022, the core solvency adequacy ratio of Fosun United Health dropped to 56.77%, and the comprehensive solvency adequacy ratio fell to 113.55%, nearing regulatory limits [3]. - By the end of 2023, these solvency ratios further declined to 55.34% and 110.67%, respectively [3]. - Following the capital increase in April 2024, the company's solvency ratios improved significantly, with the core solvency adequacy ratio reaching 114.88% and the comprehensive solvency adequacy ratio at 166.85% by June 2025 [3].

Core Viewpoint - Fosun United Health Insurance Co., Ltd. has successfully completed a strategic capital increase of 810 million yuan, raising its registered capital from 694.44 million yuan to 1.01085 billion yuan, marking a significant milestone in its capital strength and shareholder structure [1] Group 1: Capital Increase and Shareholder Changes - On September 22, 2023, Fosun United Health received approval from the Guangdong Financial Regulatory Bureau for a capital increase of 810 million yuan [1] - The new shareholders include the International Finance Corporation (IFC) and the Asian Development Bank (ADB), while existing shareholder Fosun Pharma increased its stake from 14% to 20.05%, becoming the largest shareholder [1] - The capital increase involved the issuance of 316.41 million new shares, with subscriptions from Fosun Pharma, IFC, and ADB [1] Group 2: Financial Performance - Since its establishment in January 2017, Fosun United Health has seen continuous growth in premium income, with figures rising from 0.59 million yuan in 2017 to 5.226 billion yuan in 2024, while net profits have fluctuated, with a notable turnaround in the first half of 2025, achieving a net profit of 33 million yuan [2] - In the first half of 2025, the company reported insurance business income of 3.642 billion yuan, a year-on-year increase of 31.09% [2] Group 3: Solvency Situation - As of the end of 2022, the core solvency adequacy ratio of Fosun United Health dropped to 56.77%, and the comprehensive solvency adequacy ratio fell to 113.55%, nearing regulatory limits [3] - By the end of 2023, these solvency ratios further declined to 55.34% and 110.67%, respectively [3] - Following the capital increase in April 2024, the company's solvency ratios improved significantly, with the core solvency adequacy ratio reaching 114.88% and the comprehensive solvency adequacy ratio at 166.85% by the end of June 2025 [3]